Forest Presents Phase IIb Study Of Oglemilast In COPD
Forest Laboratories and Glenmark Pharmaceuticals, a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a phase IIb dose range-finding study of oglemilast in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.